iiinova — where your digital self keeps evolving

Ajai Chari

@ajaichari.bsky.social

Director of Multiple Myeloma Program and Professor of Clinical Medicine, University of California San Francisco. Views are my own.

Posts Replies Media

Reposted by Ajai Chari

Arvind Suresh @arvindsuresh1.bsky.social · 18/10/2025

How should we choose optimal salvage treatments following BCMA-directed CAR-T therapy in multiple myeloma? Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team at @ucsfcancer.bsky.social #MMsm #myeloma dx.doi.org/10.1080/1750...

Our strategy to address relapse after BCMA CAR T-cell therapy depends on whether a patient has rapid aggressive relapse (i.e., extramedullary disease, plasma cell leukemia, or rapidly rising myeloma markers or disease burden) or biochemical/clinical relapse without aggressive features. For all patients, talquetamab or another GPRC5D bispecific is a preferred approach. For rapid aggressive relapse, high dose cytotoxic chemotherapy or salvage autologous stem cell transplant may also be considered. For other relapses, a retrial of BCMA targeted therapy or various proteasome inhibitor and immunomodulatory drug combinations can be considered. The rapidly changing landscape of available drugs means that several novel approaches or clinical trials may also be available for patients.

131

Ajai Chari @ajaichari.bsky.social · 19/01/2025

@drkomanduri.bsky.social

000

Ajai Chari @ajaichari.bsky.social · 19/01/2025

We are thrilled that the brilliant and innovative @simone-minnie will be joining UCSF myeloma program. She and her lab (positions open! aprecruit.ucsf.edu/JPF05438) will tackle some of the most pressing ?s in MM - mechanisms of T cell redirection resistance & optimal sequencing.

aprecruit.ucsf.edu

Minnie Lab - Junior, Assistant, or Associate Specialist

University of California, San Francisco is hiring. Apply now!

161